Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults ≥50 years

Key Points

• This research aims to assess the safety and durability of antibody responses to the mRNA-1083 vaccine in older adults after six months.
• Conducted a randomized trial with adults aged 50 years and older.
• Evaluated antibody responses to both influenza and SARS-CoV-2 after a single vaccine dose.
• Trial registered under NCT06097273.
• Antibody responses to SARS-CoV-2 were significant at six months post-vaccination.
• Influenza antibody levels showed sustained durability after six months.
• Safety profile indicated no severe adverse events related to the vaccine.